查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1365810

專利藥品市場：按劑型、適應症、配銷通路分類：2023-2032年全球機會分析與產業預測

Patented Drugs Market By Dosage Form, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 263 Pages | 商品交期: 2-3個工作天內

價格

2022年專利藥品市值為8,145億美元，預計2023年至2032年年複合成長率為6%，到2032年將達到14,565億美元。

專利藥品市場-IMG1

專利藥品市場的成長是由開發新藥研究活動的增加，生物技術和 3D 建模的進步以及患有慢性病的人數增加所推動的。研究人員探索各種疾病機制、分子途徑和藥物標靶，以確定治療性介入的潛在領域。這為開發新藥創造了機會，並支持專利藥物市場的成長。此外，全球心血管疾病、癌症、糖尿病、呼吸系統疾病和神經系統疾病等慢性疾病的盛行率穩定上升。例如，美國癌症協會（ACS）估計，2021年美國將診斷出約190萬新癌症病例。現有的癌症專利藥物包括Avastin、Cyprolis 和Ibrance。此類慢性疾病的增加導致對有效治療方法和管理策略的需求不斷增加，推動了專利藥物市場的成長。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 加大研發投入
      • 疾病負擔迅速增加
    • 抑制因素
      • 專利藥高成本
    • 機會
      • 強大的智慧財產權
  • COVID-19 市場影響分析

第4章 專利藥品市場：按劑型

  • 概述
  • 固態藥物
  • 藥液
  • 其他

第5章 專利藥品市場：依適應症分類

  • 概述
  • 心血管疾病
  • 癌症
  • 自體免疫疾病
  • 其他

第6章 專利藥品市場：按配銷通路

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥房

第7章 專利藥品市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Bayer AG
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Biogen
  • Astellas Pharma Inc.
Product Code: A110993

According to a new report published by Allied Market Research, titled, "Patented Drugs Market," The patented drugs market was valued at $814.5 billion in 2022, and is estimated to reach $1,456.5 billion by 2032, growing at a CAGR of 6% from 2023 to 2032.

Patented Drugs Market - IMG1

The patented drugs market growth is driven by increase in the number of research activities for development of new drugs, advancement in biotechnology and 3D modeling, and rise in people suffering from chronic diseases. Researchers explore various disease mechanisms, molecular pathways, and drug targets to identify potential areas for therapeutic intervention. This creates opportunities for the development of new drugs which drives the growth of patented drugs market. Furthermore, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, respiratory disorders, and neurological conditions, has been steadily rising globally. For instance, in 2021 American Cancer Society (ACS), estimated that about 1.9 million new cancer cases were diagnosed in the U.S. The available patented drugs for cancer include Avastin, KYPROLIS, IBRANCE, and others. This rise in chronic diseases has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the patented drugs market.

In addition, the availability of robust regulatory authorities such as U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) determines the drug approval process and grant market exclusivity to pharmaceuticals. This exclusivity period provide advantages for pharmaceutical companies, enabling them to recover their investment and generate revenue from patented drugs. Furthermore, increase in number of patent application filing in 2022 further boost the growth of the patented drugs market. For instance, in 2022, European Patent Office (EPO), received a total of 193,460 applications. It was also reported that patent activity in pharmaceuticals increased by 1% as compared to 2021.

However, entry of generic versions of the drug at lower prices after patent expiration limit the growth of the patented drugs market. The availability of cheaper alternatives may impact the demand for patented drugs. Furthermore, high costs associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new patented drugs thereby impacting the market growth. On the other hand, surge in technological advancements, such as precision medicine, genomics, proteomics, and targeted therapies, are revolutionizing drug discovery and development. These advancements enable the development of more effective and patented drugs during the forecast period.

The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into solid drug product, liquid drug product, and others. Others segments include semi-solid drug and gaseous drug. As per indication, the market is categorized into cardiovascular diseases, cancer, autoimmune diseases, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global patented drugs market are AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Biogen. Key players operating in the market have adopted patent and patent extension as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patented drugs market analysis from 2022 to 2032 to identify the prevailing patented drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the patented drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global patented drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Pharmacies

By Dosage Form

  • Solid Drug Product
  • Liquid Drug Product
  • Others

By Indication

  • Cardiovascular Diseases
  • Cancer
  • Autoimmune Diseases
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amgen Inc.
    • Pfizer Inc.
    • AstraZeneca plc
    • Bayer AG
    • Biogen
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • AbbVie Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in investment in research and development activities
      • 3.4.1.2. Surge in disease burden
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of patented drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Strong intellectual property rights
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PATENTED DRUGS MARKET, BY DOSAGE FORM

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Solid Drug Product
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Liquid Drug Product
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PATENTED DRUGS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cardiovascular Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Autoimmune Diseases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PATENTED DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Dosage Form
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Dosage Form
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Dosage Form
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Dosage Form
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Dosage Form
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Dosage Form
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Dosage Form
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Dosage Form
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Dosage Form
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Dosage Form
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Dosage Form
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Dosage Form
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Dosage Form
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Dosage Form
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Dosage Form
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Dosage Form
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Dosage Form
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Dosage Form
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Dosage Form
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Dosage Form
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Dosage Form
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Dosage Form
      • 7.5.5.3.3. Market size and forecast, by Indication
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Dosage Form
      • 7.5.5.4.3. Market size and forecast, by Indication
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Amgen Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Pfizer Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. AstraZeneca plc
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Bayer AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Johnson & Johnson
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. F. Hoffmann-La Roche AG
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Biogen
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Astellas Pharma Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 02. PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PATENTED DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. PATENTED DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 11. PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. PATENTED DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 20. U.S. PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. CANADA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 23. CANADA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. UK PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 39. UK PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. UK PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. ITALY PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 42. ITALY PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 43. ITALY PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. CHINA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 58. CHINA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 59. CHINA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. INDIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 61. INDIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 62. INDIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA PATENTED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA PATENTED DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 89. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 90. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 91. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 92. AMGEN INC.: KEY EXECUTIVES
  • TABLE 93. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 94. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 96. PFIZER INC.: KEY EXECUTIVES
  • TABLE 97. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 98. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 99. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 100. PFIZER INC.: KEY STRATERGIES
  • TABLE 101. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 102. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 103. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 104. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 105. NOVARTIS AG: KEY STRATERGIES
  • TABLE 106. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 107. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 108. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 109. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 110. BAYER AG: KEY EXECUTIVES
  • TABLE 111. BAYER AG: COMPANY SNAPSHOT
  • TABLE 112. BAYER AG: PRODUCT SEGMENTS
  • TABLE 113. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 114. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 115. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 116. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 117. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 118. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 119. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 120. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 121. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 122. BIOGEN: KEY EXECUTIVES
  • TABLE 123. BIOGEN: COMPANY SNAPSHOT
  • TABLE 124. BIOGEN: PRODUCT SEGMENTS
  • TABLE 125. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 126. BIOGEN: KEY STRATERGIES
  • TABLE 127. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 128. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 129. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 130. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PATENTED DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PATENTED DRUGS MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PATENTED DRUGS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL PATENTED DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. PATENTED DRUGS MARKET, BY DOSAGE FORM, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR SOLID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR LIQUID DRUG PRODUCT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. PATENTED DRUGS MARKET, BY INDICATION, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PATENTED DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. PATENTED DRUGS MARKET BY REGION, 2022(%)
  • FIGURE 24. U.S. PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA PATENTED DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: PATENTED DRUGS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 70. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)